安徽医科大学学报
安徽醫科大學學報
안휘의과대학학보
ACTA UNIVERSITY MEDICINALIS ANHUI
2014年
6期
780-784
,共5页
雷蔚%莫新玲%谢福生%刘琼%廖发荣
雷蔚%莫新玲%謝福生%劉瓊%廖髮榮
뢰위%막신령%사복생%류경%료발영
氨氯地平%替米沙坦%复方阿米洛利%原发性高血压%药物疗法%联合
氨氯地平%替米沙坦%複方阿米洛利%原髮性高血壓%藥物療法%聯閤
안록지평%체미사탄%복방아미락리%원발성고혈압%약물요법%연합
amlodipine%telmisartan%amiroride%essential hypertensive%drug therapy%combination
目的:探讨以氨氯地平为基础的联合治疗方案,对原发性高血压患者降压疗效的比较。方法收集51~72岁伴心血管病危险因素的原发性高血压患者55例。采用多中心随机开放对照盲终点评估的临床试验方法将患者随机分为A组(28例):低剂量氨氯地平(2.5 mg/d)+复方阿米洛利(半片/d);B组(27例):低剂量氨氯地平(2.5 mg/d)+替米沙坦(40 mg/d),计划治疗随访3年。观察两组原发性高血压患者血压的变化。结果 A、B两组原发性高血压患者的血压达标率分别为 A组85.7%(1年)、89.3%(2年)和96.4%(3年)和B组66.7%(1年)、85.2%(2年)和96.3%(3年),收缩压和舒张压与基线值比较均有显著降低(P<0.05),但两组间收缩压与舒张压比较差异无统计学意义( P>0.05)。结论早期资料分析提示患者多为高危人群,随机分配良好;以氨氯地平为基础的联合治疗均能有效降低血压,仅在第1年氨氯地平联合复方阿米洛利的血压达标率高于氨氯地平联合替米沙坦的血压达标率。
目的:探討以氨氯地平為基礎的聯閤治療方案,對原髮性高血壓患者降壓療效的比較。方法收集51~72歲伴心血管病危險因素的原髮性高血壓患者55例。採用多中心隨機開放對照盲終點評估的臨床試驗方法將患者隨機分為A組(28例):低劑量氨氯地平(2.5 mg/d)+複方阿米洛利(半片/d);B組(27例):低劑量氨氯地平(2.5 mg/d)+替米沙坦(40 mg/d),計劃治療隨訪3年。觀察兩組原髮性高血壓患者血壓的變化。結果 A、B兩組原髮性高血壓患者的血壓達標率分彆為 A組85.7%(1年)、89.3%(2年)和96.4%(3年)和B組66.7%(1年)、85.2%(2年)和96.3%(3年),收縮壓和舒張壓與基線值比較均有顯著降低(P<0.05),但兩組間收縮壓與舒張壓比較差異無統計學意義( P>0.05)。結論早期資料分析提示患者多為高危人群,隨機分配良好;以氨氯地平為基礎的聯閤治療均能有效降低血壓,僅在第1年氨氯地平聯閤複方阿米洛利的血壓達標率高于氨氯地平聯閤替米沙坦的血壓達標率。
목적:탐토이안록지평위기출적연합치료방안,대원발성고혈압환자강압료효적비교。방법수집51~72세반심혈관병위험인소적원발성고혈압환자55례。채용다중심수궤개방대조맹종점평고적림상시험방법장환자수궤분위A조(28례):저제량안록지평(2.5 mg/d)+복방아미락리(반편/d);B조(27례):저제량안록지평(2.5 mg/d)+체미사탄(40 mg/d),계화치료수방3년。관찰량조원발성고혈압환자혈압적변화。결과 A、B량조원발성고혈압환자적혈압체표솔분별위 A조85.7%(1년)、89.3%(2년)화96.4%(3년)화B조66.7%(1년)、85.2%(2년)화96.3%(3년),수축압화서장압여기선치비교균유현저강저(P<0.05),단량조간수축압여서장압비교차이무통계학의의( P>0.05)。결론조기자료분석제시환자다위고위인군,수궤분배량호;이안록지평위기출적연합치료균능유효강저혈압,부재제1년안록지평연합복방아미락리적혈압체표솔고우안록지평연합체미사탄적혈압체표솔。
Objective To evaluate efficacy of amlodipine-based antihypertensive combination regimens on blood pressure control in essential hypertension patients. Methods A total of 55 essential hypertensive patients in Guilin were included in this multi-centre randomized, controlled, and blind-endpoint assessment clinical trial. Inclusion criteria were: essential hypertension, 51 ~72 years of age with at least one cardiovascular risk factor and signed consent forms. Patients were randomly assigned to receive either ( group A ) low-dose amlodipine +diuretics or ( group B) low-dose amlodipine+telmisartan. All patients were monitored for the change of their blood pressure o-ver a period of three years. Results Clinical research indicated the blood pressure control rates were: Group A was 85. 7 % (1 year) , 89. 3 % (2 years) and 96. 4 % (3 years) . Group B was 66. 7 % (1 year) , 85. 2 % (2 years) and 96. 3% (3 years) . For all patients from both groups, the systolic and diastolic blood pressure compared with baseline values were significantly reduced ( P <0. 05 ) . However, the systolic and diastolic blood pressure difference between the two groups was not statistically significant ( P >0 . 05 ) . Conclusion Early data analysis suggests that most of patients enrolled in this study are from high-risk population, and randomly assigned to two treatment groups. Amlodipine-based antihypertensive combination regimens achieves satisfactory blood pressure control rate. During the first year of treatment, the blood pressure control rate with the double combo of amlodipine and amiloride is much higher than the group with the double combo of amlodipine and aelmisartan.